entertainment -WSS

entertainment

author：comprehensive 2025-08-19 12:15:07 - browse：92

Two people run on the sugar-phosphate backbone of DNA while holding base pairs — in the lab coverage from STAT — Adobe

LONDON — Widespread genetic testing as well as the development of cutting-edge, customized genetic therapies have opened the door to treating many more inherited conditions than previously possible. A few recent cases, in which bespoke medicines were created for children with exceedingly rare mutations, have raised hopes for furthering the approach.

Now, researchers and government agencies in the U.K. are trying to figure out the nitty-gritty to replicate those early one-off successes for as many patients as possible — what sort of preclinical testing a tailor-made treatment needs to go through before being used, what regulatory thresholds each treatment needs to clear, and how to pay for these therapies.

“A lot of the barriers are no longer scientific — we can make these drugs,” said Matthew Wood, a professor of pediatrics at the University of Oxford. “It’s more about, can we make them at a cost that is reasonable enough? And can we get the regulators to reduce the barriers to doing this so that when a patient shows up, you can actually make a drug quickly enough to benefit that patient, rather than it costing huge amounts of money and taking two or three years to do it?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Fight over Supreme Court dialysis ruling puts kidney patients at risk

WSS

Radiology is caught between AI's potential and concern for patients

Data don't support strong claims for Covid

Radiology is caught between AI's potential and concern for patients

SCOTUS to consider access to abortion pill mifepristone

Anthony Fauci pushes back on GOP claims during Covid hearing

Data don't support strong claims for Covid

leisure time

entertainment

entertainment

How to save PrEP access — and even expand it

Roche to buy Carmot Therapeutics, developer of obesity drugs

Moonlake's readout produced a cash windfall. Risks remain

FDA needs staff influx to meet gene therapy needs, Marks says

Apple is now the first public company to be valued at $3 trillion

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Heart attack and stroke risk calculators need revising

Pharma patents targeted by Biden in move to slash drug prices

In age of alternative facts, a scholarly course on calling out crap

Leukemia patients are helped by Syndax's new type of therapy

entertainment

Chemotherapy shortages won’t get better under Biden’s latest plan

Structure Therapeutics oral GLP

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

CMS should re

Stopping antidepressants leads to symptoms for 1 in 6 patients

BD to buy Edwards patient monitoring unit for $4.2 billion

hotspot

explore

knowledge

leisure time